ArticleBMC infectious diseases2025
Prevalence of drug resistance mutations and their association with time to virological failure in people living with HIV in Uganda.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Longitudinal analysis of viral suppression before, during, and after pregnancy among women on antiretroviral therapy in Uganda: six-year real-world experience.HIV research & clinical practice · 2026Article
- Virological impact of the programmatic dolutegravir transition at Mildmay Hospital Uganda: a before-and-after cohort study with subgroup and trajectory analysis, 2016-2023.BMC infectious diseases · 2026Article
- Viral suppression and adverse events following antiretroviral therapy optimization among children and adolescents in Uganda, 2018-2023.BMC public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDespite advancements in antiretroviral therapy (ART), virological failure and drug resistance mutations (DRMs) continue to pose major challenges, especially in resource-limited settings. This study examined DRM prevalence and their association with time to virological failure, informing strategies to optimize HIV treatment outcomes.
methodsThis cohort study retrospectively reviewed medical records of 235 People living with HIV (PLHIV) who underwent HIV drug resistance testing at the Mildmay-Uganda Hospital from 2018 to 2023. Data on demographics, ART, and DRMs were analyzed. Kaplan-Meier and log-rank tests were used to compare median time to virological failure. Cox proportional hazards models assessed associations factors associated with time to virological failure, with significance set at p < 0.05.
resultsParticipants had a mean age of 28.0 years, 11.2 years on ART, and DRMs detected in 59.6%. Mutation prevalence was NNRTIs (52.8%), NRTIs (50.2%), PI major (25.5%), and INSTI (≤ 0.9%). Key drug class mutations included, NNRTIs (K103KN 25.1%, G190AS 14.0%, Y181CF/V/F 12.3%), NRTIs (M184V 45.0%, T215FY 30.2%, M41L 18.3%), PIs (M46I 15.7%, V82VA 12.3%, I54LV 9.4%), and INSTIs (E138K, T66A, G118R, E92EV all at 0.4%). DRMs were significantly associated with longer time (months) to virological failure: NRTIs (129.3 vs. 88.2, p = 0.008), NNRTIs (127.4 vs. 84.2, p = 0.003), and PIs (170.9 vs. 88.7, p = 0.000). In cox regression analysis, time to virological failure was significantly associated with age (HR: 0.987; CI: 0.976-0.998; p = 0.019, aHR: 0.976; CI: 0.959-0.993; p = 0.007), ART duration (HR: 0.828; CI: 0.800-0.856; p = 0.000, aHR: 0.827; CI: 0.792-0.863; p = 0.000), drug mutations; NRTI (HR: 0.659; CI: 0.484-0.898; p = 0.008), NNRTI (HR: 0.628; CI: 0.463-0.851; p = 0.003), and PI (HR: 0.257; CI: 0.146-0.453; p = 0.000, aHR: 0.337; CI: 0.137-0.831; p = 0.018).
conclusionDrug resistance is common among PLHIV failing ART, dominated by NNRTI and NRTI mutations. DRMs were present among PLHIV who took a longer time to virological failure. Delayed failure was independently associated with older age, longer ART duration, and PI mutations. Findings support early DRM testing and individualized ART, especially as newer ART options emerge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.